岩盐气溶胶疗法对尘肺患者痰液炎性因子水平的影响
|
摘要
目的通过分析尘肺患者采用岩盐气溶胶治疗前后痰液中白介素6(IL-6)、白介素8(IL-8)和肿瘤坏死因子α(TNF-α)的水平,了解该疗法对尘肺患者的临床作用。方法选取6家医院于2016年11月—2017年4月收治的389例尘肺患者为研究对象,按照尘肺期别分层,随机分为治疗组和对照组,治疗组在常规治疗的基础上加做岩盐气溶胶治疗,分别在治疗前、治疗后2周和治疗后4周收集患者晨痰,经处理后检测标本中IL-6、IL-8和TNF-α的水平,并对结果进行分析。结果治疗组和对照组的痰液炎性因子水平治疗前分别为[(243.97±27.98)pg/ml比(239.86±34.80)pg/ml,(1 480.01±226.39)pg/ml比(1 463.34±234.96)pg/ml,(720.73±132.76)pg/ml比(711.59±152.85)pg/ml],治疗2周后,IL-6、IL-8、TNF-α水平治疗组低于对照组[(213.72±31.93)pg/ml比(208.42±33.38)pg/ml,(1 392.23±231.46)pg/ml比(1 416.73±224.81)pg/ml,(683.23±143.56)pg/ml比(721.33±145.85)pg/ml],治疗后4周后IL-6、IL-8和TNF-α水平治疗组均低于对照组[(169.49±19.43)pg/ml比(195.38±21.95)pg/ml,(1 233.21±141.90)pg/ml比(1 309.94±189.59)pg/ml,(578.82±96.72)pg/ml比(651.62±131.32)pg/ml],治疗组和对照组随着治疗时间的延长均有所下降,且各观察时点之间的差异有统计学意义(P<0.05);治疗后各观察时点IL-6、IL-8和TNF-α的变化水平,治疗组均大于对照组,治疗后4周差异有统计学意义(P<0.05)。结论岩盐气溶胶疗法可以降低尘肺患者痰液中炎性因子IL-6、IL-8和TNF-α的水平,在常规治疗基础上加用岩盐气溶胶疗法可以更好的降低患者气道炎性反应,治疗效果更优,可为尘肺病临床治疗提供一种有效的辅助方法。
[Objective] To analyze the levels of inflammatory factors IL-6, IL-8 and TNF-α in sputum of patients with pneumoconiosis before and after halotherapy, explore the clinical effect of the therapy on patients with pneumoconiosis.[Methods] A total of 389 patients with pneumoconiosis were selected from six hospitals during November 2016 to April 2017,the patients were stratified according to pneumoconiosis stage and were randomly divided into the treatment group and the control group. The treatment group was given halotherapy on the basis of conventional treatment. The morning sputum samples were collected before treatment, two weeks and four weeks after treatment, and the levels of IL-6, IL-8 and TNF-α in the samples were detected. The results were analyzed.[Results] Before treatment, the levels of IL-6, IL-8 and TNF-α in the treatment group and the control group were [(243.97±27.98) pg/ml vs(239.86±34.80) pg/ml,(1 480.01±226.39) pg/ml vs(1 463.34±234.96) pg/ml,(720.73±132.76) pg/ml vs(711.59±152.85) pg/ml] respectively.treatment After two weeks of treatment, the levels of IL-6, IL-8 and TNF-α in the group were lower than those in the control group [(213.72±31.93) pg/ml vs(208.42±33.38) pg/ml,(1 392.23±231.46) pg/ml vs(1 416.73±224.81) pg/ml,(683.23±143.56) pg/ml vs(721.33±145.85) pg/ml]. After four weeks of treatment,the levels of IL-6, IL-8 and TNF-α in the treatment group were lower than those in the control group [(169.49±19.43) pg/ml vs(195.38±21.95) pg/ml,(1 233.21±141.90) pg/ml vs(1 309.94±189.59) pg/ml,(578.82±96.72) pg/ml vs(651.62±131.32) pg/ml].The levels of IL-6, IL-8 and TNF-α in both treatment group and the control group decreased with treatment duration, and there were statistically significant differences among different observation time points(P<0.05). After treatment, the change levels of IL-6,IL-8 and TNF-α in the treatment group were higher than those in the control group at observation time point, and the difference after four weeks of treatment was statistically significant(P<0.05). [Conclusion] Halotherapy can reduce sputum inflammatory factor IL-6, IL-8 and TNF-α concentrations in patients with pneumoconiosis. Adding halotherapy based on routine treatment can better reduce airway inflammation sexual response, get better treatment effect and provide an effective adjunct for the clinical treatment of pneumoconiosis.
[Objective] To analyze the levels of inflammatory factors IL-6, IL-8 and TNF-α in sputum of patients with pneumoconiosis before and after halotherapy, explore the clinical effect of the therapy on patients with pneumoconiosis.[Methods] A total of 389 patients with pneumoconiosis were selected from six hospitals during November 2016 to April 2017,the patients were stratified according to pneumoconiosis stage and were randomly divided into the treatment group and the control group. The treatment group was given halotherapy on the basis of conventional treatment. The morning sputum samples were collected before treatment, two weeks and four weeks after treatment, and the levels of IL-6, IL-8 and TNF-α in the samples were detected. The results were analyzed.[Results] Before treatment, the levels of IL-6, IL-8 and TNF-α in the treatment group and the control group were [(243.97±27.98) pg/ml vs(239.86±34.80) pg/ml,(1 480.01±226.39) pg/ml vs(1 463.34±234.96) pg/ml,(720.73±132.76) pg/ml vs(711.59±152.85) pg/ml] respectively.treatment After two weeks of treatment, the levels of IL-6, IL-8 and TNF-α in the group were lower than those in the control group [(213.72±31.93) pg/ml vs(208.42±33.38) pg/ml,(1 392.23±231.46) pg/ml vs(1 416.73±224.81) pg/ml,(683.23±143.56) pg/ml vs(721.33±145.85) pg/ml]. After four weeks of treatment,the levels of IL-6, IL-8 and TNF-α in the treatment group were lower than those in the control group [(169.49±19.43) pg/ml vs(195.38±21.95) pg/ml,(1 233.21±141.90) pg/ml vs(1 309.94±189.59) pg/ml,(578.82±96.72) pg/ml vs(651.62±131.32) pg/ml].The levels of IL-6, IL-8 and TNF-α in both treatment group and the control group decreased with treatment duration, and there were statistically significant differences among different observation time points(P<0.05). After treatment, the change levels of IL-6,IL-8 and TNF-α in the treatment group were higher than those in the control group at observation time point, and the difference after four weeks of treatment was statistically significant(P<0.05). [Conclusion] Halotherapy can reduce sputum inflammatory factor IL-6, IL-8 and TNF-α concentrations in patients with pneumoconiosis. Adding halotherapy based on routine treatment can better reduce airway inflammation sexual response, get better treatment effect and provide an effective adjunct for the clinical treatment of pneumoconiosis.
引文
[1]熊政,张艳霞,焦深山.岩盐气溶胶疗法在支气管哮喘治疗中的临床疗效分析[J].中国医疗前沿,2013,8(17):27-28.
[2]姜鹏,王洋,马丽丽,等.岩盐气溶胶疗法治疗职业性哮喘临床疗效的研究[J].大家健康,2013,7(3):89.
[3]马丽丽,姜鹏,王洋,等.30例职业性哮喘岩盐气溶胶疗法的临床治疗[J].中国卫生标准,2014,5(3):36-37.
[4]王洋,刘锡诚,李京淑,等.岩盐气溶胶疗法在尘肺病合并慢性阻塞性肺疾病康复治疗中的应用评价[C].中华预防医学会劳动卫生与职业病分会.第十三次全国劳动卫生与职业病学术会议论文汇编.中华预防医学会劳动卫生与职业病分会,山东:泰安,2014:1.
[5]中华人民共和国国家卫生和计划生育委员会.职业性尘肺病的诊断:GBZ 70-2015[S].北京:中国标准出版社,2015:1-2.
[6]王焕强,李涛.尘肺病的定义与历史[J].中国职业医学,2017,44(4):485-493.
[7]邱新香,陈慈珊,巫带花,等.尘肺患者心理状况及其生活质量研究进展[J].中国职业医学,2008,35(6):521-522,524.
[8]赵庚.我国尘肺病的社会经济影响分析研究[D].北京:中国地质大学,2011:15.
[9]李霖.细胞因子和尘肺发病关系研究的进展[J].中华劳动卫生职业病杂志,2003,21(3):59-62.
[10]高衍新,万恩广,王瑞,等.矽肺患者诱导痰中白细胞介素-6、白细胞介素-16含量测定及其意义[J].预防医学论坛,2008,14(7):583-585,588.
[11]曾勉,刘凌云,张式鸿,等.各期慢性阻塞性肺疾病患者诱导痰细胞成分与肺功能的关系[J].中山大学学报:医学科学版,2007,28(4):422-425.
[12]袁志明,陈光谨,杜文斌.大鼠肺纤维化过程中肺泡巨噬细胞释放白介素6和肿瘤坏死因子α的观察[J].天津医药,1999,27(12):742-743.
[13]孙星炯,陈景藻.干盐气溶胶疗法临床应用的科学根据与展望[J].国外医学(物理医学与康复学分册),2000,20(4):158-160.
[14]李红艳,涂力,翁恒,等.岩盐气溶胶疗法在支气管哮喘治疗中的应用[J].中华结核和呼吸杂志,2011,34(1):70-71.
[2]姜鹏,王洋,马丽丽,等.岩盐气溶胶疗法治疗职业性哮喘临床疗效的研究[J].大家健康,2013,7(3):89.
[3]马丽丽,姜鹏,王洋,等.30例职业性哮喘岩盐气溶胶疗法的临床治疗[J].中国卫生标准,2014,5(3):36-37.
[4]王洋,刘锡诚,李京淑,等.岩盐气溶胶疗法在尘肺病合并慢性阻塞性肺疾病康复治疗中的应用评价[C].中华预防医学会劳动卫生与职业病分会.第十三次全国劳动卫生与职业病学术会议论文汇编.中华预防医学会劳动卫生与职业病分会,山东:泰安,2014:1.
[5]中华人民共和国国家卫生和计划生育委员会.职业性尘肺病的诊断:GBZ 70-2015[S].北京:中国标准出版社,2015:1-2.
[6]王焕强,李涛.尘肺病的定义与历史[J].中国职业医学,2017,44(4):485-493.
[7]邱新香,陈慈珊,巫带花,等.尘肺患者心理状况及其生活质量研究进展[J].中国职业医学,2008,35(6):521-522,524.
[8]赵庚.我国尘肺病的社会经济影响分析研究[D].北京:中国地质大学,2011:15.
[9]李霖.细胞因子和尘肺发病关系研究的进展[J].中华劳动卫生职业病杂志,2003,21(3):59-62.
[10]高衍新,万恩广,王瑞,等.矽肺患者诱导痰中白细胞介素-6、白细胞介素-16含量测定及其意义[J].预防医学论坛,2008,14(7):583-585,588.
[11]曾勉,刘凌云,张式鸿,等.各期慢性阻塞性肺疾病患者诱导痰细胞成分与肺功能的关系[J].中山大学学报:医学科学版,2007,28(4):422-425.
[12]袁志明,陈光谨,杜文斌.大鼠肺纤维化过程中肺泡巨噬细胞释放白介素6和肿瘤坏死因子α的观察[J].天津医药,1999,27(12):742-743.
[13]孙星炯,陈景藻.干盐气溶胶疗法临床应用的科学根据与展望[J].国外医学(物理医学与康复学分册),2000,20(4):158-160.
[14]李红艳,涂力,翁恒,等.岩盐气溶胶疗法在支气管哮喘治疗中的应用[J].中华结核和呼吸杂志,2011,34(1):70-71.